Literature DB >> 21457442

Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.

Nathalie C Leite1, Cristiane A Villela-Nogueira, Vera L N Pannain, Adriana C Bottino, Guilherme F M Rezende, Claudia R L Cardoso, Gil F Salles.   

Abstract

BACKGROUND/AIMS: Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in type 2 diabetes mellitus (T2DM). However, data regarding the prevalence and correlates of its histopathological stages are scarce. The aim was to investigate the prevalence and correlates of the more severe histopathological features of NAFLD, nonalcoholic steatohepatitis (NASH) and advanced fibrosis, in T2DM.
METHODS: From 125 patients with ultrasonographic evidence of NAFLD, 98 patients underwent liver biopsies, which were examined by two independent pathologists regarding the presence of NASH and graded according to the NASH Clinical Research Network scoring system. Agreement between pathologists was assessed by weighted κ coefficients and independent correlates of NASH and advanced fibrosis (grade ≥ 2) by multivariate logistic regression.
RESULTS: Ninety-two (94%) patients presented histological NAFLD. Interobserver agreement was substantial to excellent for NASH diagnosis (κ=0.82) and steatosis grading (κ=0.76), and moderate for the NAFLD activity score (κ=0.58) and fibrosis grading (κ=0.52). The prevalence of NASH was 78%, and its independent correlates were hypertriglyceridaemia (P=0.034), high alanine aminotranferase level (P=0.044) and low serum high-density lipoprotein-cholesterol (P=0.079). The prevalence of advanced fibrosis ranged from 34% in the best scenario (lowest fibrosis score) to 60% in the worst scenario (highest score). Its independent correlates were a high serum γ-glutamyl transferase (P=0.002), older age (P=0.022) and male gender (P=0.064). No diabetes-related clinical characteristic was associated with NASH or advanced liver fibrosis.
CONCLUSIONS: The prevalence of the severe features of NAFLD is high in T2DM patients. Liver biopsy shall be considered in all diabetic patients with ultrasonographic evidence of NAFLD.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2011        PMID: 21457442     DOI: 10.1111/j.1478-3231.2011.02482.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  50 in total

1.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

Review 2.  Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease.

Authors:  William N Hannah; Stephen A Harrison
Journal:  Dig Dis Sci       Date:  2016-05       Impact factor: 3.199

Review 3.  Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Claudia R L Cardoso; Gil F Salles
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 4.  Nonalcoholic fatty liver disease and cardiovascular disease.

Authors:  Hong Liu; Hong-Yun Lu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

5.  An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Romina Lomonaco; Janet Chen; Kenneth Cusi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 6.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

7.  Fish oil -- how does it reduce plasma triglycerides?

Authors:  Gregory C Shearer; Olga V Savinova; William S Harris
Journal:  Biochim Biophys Acta       Date:  2011-10-25

Review 8.  Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes.

Authors:  Iliana Doycheva; Niraj Patel; Michael Peterson; Rohit Loomba
Journal:  J Diabetes Complications       Date:  2013-01-09       Impact factor: 2.852

9.  Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders.

Authors:  Srinevas K Reddy; Min Zhan; H Richard Alexander; Samer S El-Kamary
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 10.  Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?

Authors:  Gábor Firneisz
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.